Chemours Q1 2025 Earnings Report
Key Takeaways
The Chemours Company reported net sales of $1.4 billion in the first quarter of 2025, in line with the prior-year quarter. The company experienced a net loss of $4 million, or $0.03 per diluted share, compared to net income of $54 million in the prior-year quarter. Adjusted EBITDA decreased by 13% year-over-year.
Net Sales in Q1 2025 were $1.4 billion, consistent with Q1 2024.
The company reported a Net Loss of $4 million in Q1 2025, a significant decrease from Net Income of $54 million in Q1 2024.
Adjusted EBITDA for Q1 2025 was $166 million, down 13% from $191 million in Q1 2024.
Free cash flow for Q1 2025 was a use of $196 million, an improvement compared to a use of $392 million in Q1 2024.
Chemours
Chemours
Chemours Revenue by Segment
Forward Guidance
For the second quarter of 2025, Chemours anticipates sequential increases in consolidated Net Sales and Adjusted EBITDA. Full-year 2025 Adjusted EBITDA is expected to range between $825 million and $950 million, with capital expenditures between $225 million and $275 million.
Positive Outlook
- Consolidated Net Sales expected to increase in the low to mid-teens sequentially in Q2 2025.
- Consolidated Adjusted EBITDA expected to increase by 40% to 45% sequentially in Q2 2025.
- TSS segment expects sequential Net Sales increase in the low 20% range in Q2 2025.
- TT segment expects sequential Net Sales increase in the high single-digits in Q2 2025.
- APM segment expects sequential Net Sales increase in the low-teens in Q2 2025.
Challenges Ahead
- Corporate Expenses are expected to decrease only in the low single-digits sequentially in Q2 2025.
- Free cash flow in the second quarter is expected to be only slightly positive.
- Full-year 2025 Adjusted EBITDA guidance range is wide ($825 million to $950 million).
- Full-year 2025 capital expenditures are projected to be significant ($225 million to $275 million).
- The outlook assumes existing tariff environment and no larger indirect impacts from tariffs or recessionary impacts.